Home > Insider Trading > Filing (0001209191-21-005162)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1322505	Albireo Pharma Inc.	ALBO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1741553	Jason Duncan	C/O Albireo Pharma Inc. 10 Post Office Square, Suite 1000 Boston MA 02109	Chief Legal Officer And Gc	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-01-21	5,500	$0.00	9,442	No	4	A	Direct
Common Stock	Disposition	2021-01-22	110	$34.62	9,332	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2021-01-21	23,700	$0.00	23,700	$34.88

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
23,700		2031-01-20	No	4	A	Direct

Footnotes

Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025.
Represents 1,129 shares of common stock and 8,313 restricted stock units. Includes 161 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on November 30, 2020.
Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Represents 1,332 shares of common stock and 8,000 restricted stock units.
This option vests as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025.